Coherus Oncology to Participate in Upcoming Investor Conferences

Company Overview - Coherus Oncology, Inc. is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi) [4] - The company has a growing revenue stream and a promising proprietary pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, and head & neck [4] Product and Pipeline - LOQTORZI is being positioned to grow sales in nasopharyngeal carcinoma and advance new indications in combination with pipeline candidates and partners [4] - The immuno-oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses for better cancer treatment outcomes [5] - Casdozokitug, a novel IL-27 antagonistic antibody, is currently in multiple Phase 1/2 and Phase 2 studies for advanced solid tumors, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [5] - CHS-114, a selective cytolytic anti-CCR8 antibody, is in Phase 1b studies for advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC), gastric cancer, and esophageal cancer [5] Upcoming Events - Coherus will be participating in several upcoming conferences, including the Baird 2025 Global Healthcare Conference on September 9, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [6] - A virtual event, UBS Virtual Oncology Day, is scheduled for October 1, 2025 [6] - Presentations will be accessible via webcast, with replays available for 30 days [1]